The US Food and Drug Administration Tuesday released a brief review speaking positively about Moderna's vaccine against COVID-19 before a meeting of experts on its emergency approval.

The agency’s statement was optimistic, saying that “there are no specific safety concerns that would prevent the urgent issuance of a license to use,” and confirmed the overall effectiveness of the vaccine at 94.1 percent.

If approved, the Moderna vaccine will join the Pfizer/BioNTech vaccine in the US vaccination campaign, the largest in US history.

The US authorities intend to vaccinate about 20 million Americans by the end of December and one hundred million by the end of March.

The United States bought 200 million doses of the Moderna vaccine, half of which will not be distributed before the second quarter of 2021. It has also bought 100 million doses of the Pfizer/BioNTech vaccine.

In the first stage, priority will be given to vaccinating medical personnel and nursing homes.

The US agency licensed the Pfizer vaccine last Thursday.

More than 300,000 people have died from COVID-19 in the United States, according to a Johns Hopkins University census.

The United States is still registering record levels of infections regularly, with 200,000 cases and 2,500-3,000 deaths per day.